Toll Free: 1-888-928-9744

Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 31 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2017, provides an overview of the Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline landscape.

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain caused by lytic infection of oligodendrocytes by the JC polyomavirus. Symptoms include clumsiness, progressive weakness, and visual, speech, and sometimes personality changes. Risk factors include the presence of pathogenic JCV and an altered or weakened immune system, genetic or environmental factors.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 5 and 3 respectively.

Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Multifocal Leukoencephalopathy (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Progressive Multifocal Leukoencephalopathy - Overview Progressive Multifocal Leukoencephalopathy - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Progressive Multifocal Leukoencephalopathy - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Molecule Type Progressive Multifocal Leukoencephalopathy - Companies Involved in Therapeutics Development Excision BioTherapeutics Inc Humabs BioMed SA Neurimmune Holding AG Neuway Pharma GmbH Pomona Ricerca SRL Progressive Multifocal Leukoencephalopathy - Drug Profiles EBT-103 - Drug Profile Product Description Mechanism Of Action R&D Progress IKT-01427 - Drug Profile Product Description Mechanism Of Action R&D Progress imatinib mesylate - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody for JCV and BKV Infections - Drug Profile Product Description Mechanism Of Action R&D Progress NI-307 - Drug Profile Product Description Mechanism Of Action R&D Progress NPW-007 - Drug Profile Product Description Mechanism Of Action R&D Progress PNJC-1 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile Product Description Mechanism Of Action R&D Progress Progressive Multifocal Leukoencephalopathy - Dormant Projects Progressive Multifocal Leukoencephalopathy - Product Development Milestones Featured News & Press Releases May 21, 2014: Inhibikase Therapeutics Receives Orphan Drug Designation for treatment of Progressive Multifocal Leukoencephalopathy Apr 25, 2013: Inhibikase Therapeutics To Present Data On IkT-001Pro At 5th International Congress On Polyomaviruses And Human Diseases Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Progressive Multifocal Leukoencephalopathy - Pipeline by Excision BioTherapeutics Inc, H1 2017 Progressive Multifocal Leukoencephalopathy - Pipeline by Humabs BioMed SA, H1 2017 Progressive Multifocal Leukoencephalopathy - Pipeline by Neurimmune Holding AG, H1 2017 Progressive Multifocal Leukoencephalopathy - Pipeline by Neuway Pharma GmbH, H1 2017 Progressive Multifocal Leukoencephalopathy - Pipeline by Pomona Ricerca SRL, H1 2017 Progressive Multifocal Leukoencephalopathy - Dormant Projects, H1 2017



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify